Taken together, these results demonstrate that MmPah mRNA-based therapy targeted to the liver expressed functional PAH protein, which is well tolerated and effective in reducing the accumulation of Phe in serum, livers, and brains of PKU mice. The gene discussed is PAH; the disease is phenylketonuria.